- 1
- 2 Full title:
- 3 Transcriptomic meta-analysis of non-Hodgkin's B-cell lymphomas
- 4 reveals reliance on pathways associated with the extracellular matrix
- 5
- 6 Short title:
- 7 Transcriptomic meta-analysis of non-Hodgkin's B-cell lymphomas
- 8
- 9 Authors: Naomi Rapier-Sharman¹, Jeffrey Clancy¹, and Brett E. Pickett^{1,*}
- ¹ Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT
- 11 84602
- 12 *Corresponding author; email: brett_pickett@byu.edu, phone: 801-422-2506, address: 3141 LSB
- 13 Provo, UT 84602-1050
- 14
- 15
- 16
- 17
- 18
 - 0
- 19
- 20
- . .
- 21
- 22
- 23
- 24
 - 25

26 Abstract

27 Approximately 450,000 cases of Non-Hodgkin's lymphoma are diagnosed annually worldwide, 28 resulting in ~240,000 deaths. An augmented understanding of the common mechanisms of 29 pathology among relatively large numbers of B-cell Non-Hodgkin's Lymphoma (BCNHL) patients 30 is sorely needed. We consequently performed a large transcriptomic meta-analysis of available 31 BCNHL RNA-sequencing data from GEO, consisting of 322 relevant samples across ten distinct 32 public studies, to find common underlying mechanisms across BCNHL subtypes. The study was 33 limited to GEO's publicly available human B-cell RNA-sequencing datasets that met our criteria, 34 and limitations may include lack of diversity in ethnicities and age groups. We found ~10,400 35 significant differentially expressed genes (FDR-adjusted p-value < 0.05) and 33 significantly 36 modulated pathways (Bonferroni-adjusted p-value < 0.05) when comparing lymphoma samples to 37 non-diseased samples. Our findings include a significant class of proteoglycans not previously 38 associated with lymphomas as well as significant modulation of extracellular matrix-associated 39 proteins. Our drug prediction results yielded new candidates including ocriplasmin and 40 collagenase. We also used a machine learning approach to identify the BCNHL biomarkers 41 YES1, FERMT2, and FAM98B, novel biomarkers of high predictive fidelity. This meta-analysis 42 validates existing knowledge while providing novel insights into the inner workings and 43 mechanisms of B-cell lymphomas that could give rise to improved diagnostics and/or 44 therapeutics. No external funding was used for this study.

45

46 Introduction

Lymphomas are cancers of the blood. In 2016, there were 461,000 cases of Non-Hodgkin's
lymphoma worldwide, resulting in 240,000 deaths (1). Among non-Hodgkin's lymphomas, only
~10-15% are T-cell lymphomas, while the remaining 85-90% are B-cell malignancies (2). B-cell
Non-Hodgkin's Lymphomas (BCNHLs) pose a significant disease burden worldwide. BCNHL
subtypes include Burkitt's lymphoma, nodal, extra-nodal, and splenic marginal-zone B-cell

52	lymphomas, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, post-
53	transplantation lymphoproliferative disorders, small lymphocytic lymphoma, lymphoblastic
54	lymphoma, lymphoplasmacytic lymphoma, and lymphomatoid granulomatosis (2). B-cell
55	lymphomas are dependent on their extracellular environment for activation and transformation
56	into malignancies, including antigen activation of the B-cell receptor, canonical B-cell growth
57	signals which are also essential to the maturation of healthy B-cells, and signals delivered by
58	other immune cells in the follicular/germinal center lymphoma microenvironment (3).
59	
60	The research community has dedicated extensive effort to identify the attributes that characterize
61	cancers across all subtypes. Specifically, it has been suggested previously that all cancers share
62	the following traits: selective proliferative advantage, altered stress response, vascularization,
63	invasion and metastasis, metabolic rewiring, immune modulation, and an abetting
64	microenvironment (4,5). One example of a molecular mechanism that is common in cancer is
65	malignant development through TP53 mutation, with multiple mutations in the TP53 being
66	associated with hundreds of cancer subtypes (6). Though not every gene-mechanism pairing will
67	be found across malignant cells like TP53, it is logical to assume that identifying shared genes

68 and mechanisms by meta-analyzing previous research in a focused set of related cancer

69 subtypes can be beneficial. We can therefore leverage known mechanisms from well-studied

50 subtypes to enable quicker, less expensive mechanism discovery for understudied subtypes. This

approach could potentially enable researchers to develop safe and effective treatments.

72

The widespread adoption of RNA-sequencing (RNA-seq) has opened new frontiers in disease research. Rather than identifying and characterizing individual proteins, transcriptomic metaanalyses can provide a mechanistic snapshot of the many upregulated or downregulated genes that are affected in response to a given stimulus, such as lymphoma. Monitoring these transcriptional patterns can aid in the identification of genes that could be worth further experimental investigation due to their selective modulation in diseased samples. Though the

79	RNA-sequencing samples in the current study were previously published, compiling them into a
80	meta-analysis can grant us new insights into disease mechanisms by increasing the signal of
81	significant genes and reducing the statistical "noise" caused by outliers.
82	
83	The aim of this study was to identify some of the shared underlying molecular mechanisms and
84	biomarkers of B-cell lymphomas by performing a meta-analysis of transcriptomic data from
85	publicly available B-cell Non-Hodgkin's Lymphomas (BCNHLs) clinical samples. We expect our
86	analysis to validate past findings of B-cell cancer mechanisms and uncover mechanisms that
87	have not been previously associated with BCNHL.

88

89 **Results**

90 We acquired our BCNHL samples from the NCBI Gene Expression Omnibus (GEO) using the 91 search term, "b-cell lymphoma" with the goal of finding B-cell non-Hodgkin's lymphoma samples 92 and healthy B-cell controls. We excluded non-human samples, cell lines, formalin-fixed paraffin-93 embedded tissues, gene expression microarray experiments, single-cell (10X) RNA-sequencing 94 experiments, xenografts, samples known to be infected with EBV and KSHV, and samples which 95 contained more diverse cell types (i.e., whole blood, lymph node, PBMCs, brain, etc.). We 96 intentionally decided to not include multiple myeloma, leukemia, and Hodgkin's lymphoma 97 samples in favor of focusing on B-cell non-Hodgkin's lymphomas. We then located more healthy 98 B-cell control samples from BCNHL-unrelated studies to even out case and control numbers, the 99 final three studies cited in Table 1. Our final dataset included a total of 322 samples (134 BCNHL 100 samples and 188 healthy B-cell controls) from ten studies (Fig 1, Table 1, S1 File) (7-18). The 101 samples included in our meta-analysis were all clinical samples. The risk of synthesizing study 102 results and accounting for heterogeneity were reduced due to the lack of treatment metadata and 103 patient outcome data as input to our analysis. Given that the aim of this study was to compare the maximum number of BCNHL samples to healthy B-cells, the only source of heterogeneity that we 104

- are concerned with is the distribution of BCNHL samples across the included subtypes. Our study
- 106 was limited to GEO's publicly available human B-cell RNA-sequencing datasets that met our
- 107 criteria, and limitations may include lack of diversity in ethnicities and age groups.

108 Figure 1. PRISMA flow diagram for transparent reporting of meta-analysis study selection.

109 Contains a study-by-study breakdown of selection criteria. All studies included were retrieved 110 from the Gene Expression Omnibus (GEO) database hosted by NCBI.

111

112 Table 1. Study-based origin of samples included in the meta-analysis.

113

	Single End or Paired		Relevant
Sample Phenotype	End Reads	GEO Accession #	Samples
Large B-Cell Lymphoma	Paired End	GSE153437 (7)	25
Diffuse Large B-Cell Lymphoma	Paired End	GSE130751 (8)	63
B-Cell Lymphoma + Healthy	Single End	GSE110219 (9)	2
Diffuse Large B-Cell Lymphoma	Paired End	GSE95013 (10)	28
Follicular Lymphoma + Healthy	Paired End	GSE62241 (11,12)	14
Diffuse Large B-Cell Lymphoma	Paired End	GSE50514 (13)	7
Healthy	Paired End	GSE45982 (14,15)	8
Healthy	Single End	GSE92387 (16)	12
Healthy	Paired End	GSE118254 (17)	147
Healthy	Paired End	GSE110999 (18)	16

114 The samples used in this meta-analysis all originate from publicly-available RNA-sequencing 115 projects and can be found on NCBI's GEO.

116 117

118 We began by trimming, mapping, and quantifying the reads prior to calculating the significant 119 differential gene expression when comparing the Lymphoma to the non-diseased control 120 samples. This comparison returned ~13,800 significant differentially expressed genes (DEGs) (Figs 2 and 3, Table 2, S2 File). We then ranked this list by the FDR-corrected p-value for each 121 122 gene. We observed that the top 20 DEGs include accepted biomarkers of various Lymphomas. 123 Specifically, we confirmed several genes that have previously been explored or characterized in 124 various subtypes of BCNHL including Apolipoprotein C1 (APOC1; logFC = 6.93, FDR = 8.55 x 10^{-117}) and Vascular cell adhesion molecule 1 (VCAM1; logFC = 7.85, FDR = 2.29 × 10^{-120}) to be 125 126 upregulated in BCNHLs. We also found two pathological BCNHL genes, C-C motif chemokine ligand 18 (CCL18; logFC = 10, FDR = 3.74×10^{-123}) and C-X-C motif chemokine ligand 9 127

(CXCL9; logFC = 11, FDR = 4.31×10^{-141}) to be upregulated in BCNHL as compared to healthy 128

129 B-cells.

Figure 2. Visualization of Differentially Expressed Genes and Gene Ontologies. 130

131 Differentially expressed gene volcano plot. Green dots represent genes which were not

132 significantly differentially expressed between healthy B-cells and BCNHL, while the salmon and 133 blue dots represent underexpressed and overexpressed genes respectively.

134

135 Figure 3. Visualization of Gene Ontology Terms.

136 Gene ontology visualization. Each rectangle represents a gene ontology term found in the KEGG 137 Brite gene ontology hierarchy. The size of each rectangle corresponds to the number of BCNHL 138 differentially expressed genes present in that category. The color of each rectangle corresponds 139 to the average log₂ fold change of the genes included in that gene ontology. No KEGG Brite gene 140 ontologies were found to be significantly differentially expressed by the bc3net hypergeometric 141 enrichment.

Log₂ Fold

FDR-

142

..... 14

144

L43	Table 2. Top 20 significant differentially expressed genes.

Ensembl ID

144	

Gene

	Symbol	LIBEIIDID	Change	corrected
	-		-	p-value
1	LUM	ENSG00000139329	11.1	1.11 × 10 ⁻¹⁴⁵
2	CXCL9	ENSG00000138755	11	4.31×10^{-141}
3	C1QC	ENSG00000159189	9.65	2.70×10^{-132}
4	C1QA	ENSG00000173372	9.54	2.03×10^{-123}
5	CCL18	ENSG00000278167	10	3.74×10^{-123}
6	VCAM1	ENSG00000162692	7.58	2.29×10^{-120}
7	C1QB	ENSG00000173369	9.4	8.19 × 10 ⁻¹¹⁹
8	APOC1	ENSG00000130208	6.93	8.55×10^{-117}
9	AL512646.1	ENSG00000203396	-15.6	2.24×10^{-115}
10	CCL19	ENSG00000172724	8.48	1.27 × 10 ⁻¹¹¹
11	SLAMF8	ENSG00000158714	7.77	4.01 × 10 ⁻¹¹¹
12	COL3A1	ENSG00000168542	10.1	1.67 × 10 ⁻¹¹⁰
13	TCIM	ENSG00000176907	8.07	7.86×10^{-110}
14	RARRES2	ENSG00000106538	7.25	8.21 × 10 ⁻¹⁰⁹
15	CXCL13	ENSG00000156234	8.8	1.72 × 10 ⁻¹⁰⁷
16	SPARCL1	ENSG00000152583	7.24	6.42×10^{-107}
17	PTGDS	ENSG00000107317	7.69	1.07×10^{-105}
18	COL1A2	ENSG00000164692	8.33	3.70×10^{-102}
19	CXXC5	ENSG00000171604	-2.73	3.70×10^{-102}
20	C1R	ENSG00000159403	4.7	1.41×10^{-100}
The	top 20 differentia	ally expressed genes betw	veen BCNHL a	nd healthy B-cell

145 The top 20 differentially expressed genes between BCNHL and healthy B-cell samples. This list

146 includes genes that have been previously researched in conjunction with BCNHL as well as novel 147 genes.

148 We then examined the highest-ranking differentially expressed genes from our meta-analysis to 149 identify gene-based mechanisms of disease. The first gene we observed using this approach was 150 Lumican (LUM), which is a member of the small leucine-rich proteoglycans (SLRPs) (19), and 151 was substantially upregulated in lymphoma (log₂ fold change = 11.1, FDR p-value = 1.11 x 10⁻¹⁴⁵). In addition, the larger family of SLRPs appears to play a role in BCNHL (Table 2). 152 153 Specifically, our data show that 12/18 SLRPs are expressed in cancerous B-cells, and that 11/12 154 B-cell-expressed SLRPs are significantly differentially expressed in BCNHL samples. We found 155 that overall, the SLRP fold changes substantially differed (9/12 expressed SLRPs are 156 upregulated, 2/12 are downregulated, 1/12 had no significant change), with the genes encoding 157 SLRPs (especially Classes I and V) being well represented in the B-cell lymphoma transcriptome.

Table 3. Differential expression of members of the Small Leucine-Rich Proteoglycan
 Family (SLRPs).

160

SLRP Class	Name	Log₂ Fold Change	FDR-corrected p-value
Class I	DCN	2.88	1.67 × 10 ⁻⁴¹
	BGN	7.88	3.22 × 10 ⁻⁹⁵
	ASPN	3.09	2.27 × 10 ⁻²⁵
	ECM2	2.1	1.44×10^{-17}
	ECMX	NP	NP
Class II	FMOD	5.71	3.86×10^{-61}
	LUM	11.1	1.11 × 10 ⁻¹⁴⁵
	PRELP	0.617	1.54×10^{-4}
	KERA	NP	NP
	OMD	NP	NP
Class III	EPYC	NP	NP
	OPTC	NP	NP
	OGN	NS	NS
Class IV	CHAD	-3.49	1.33 × 10 ⁻²⁴
	NYX	NP	NP
	TSKU	1.37	1.62×10^{-16}
Class V	PODN	1.66	5.70×10^{-10}
	PODNL1	-1.49	3.15 × 10 ⁻¹¹

161 Out of the 18 members of the SLRP family, 12 are expressed in B-cells and 11 are significantly 162 differentially expressed between BCNHL and healthy B-cells. This is a novel finding.

163 *NS = not significant; NP = not present.

164

165 Complement proteins are typically regarded as components of the innate immune system, which

166 bind to antigen-antibody complexes to facilitate the formation of the membrane attack complex.

167 We found that genes encoding the Complement C1g A (C1QA; logFC = 9.54, FDR = 2.03 x 10^{-123}), Complement C1q B (C1QB; logFC = 9.4, FDR = 8.19 × 10^{-119}) and Complement C1q C 168 (C1QC; logFC = 9.65, FDR = 2.7×10^{-132}) chains were all dramatically and significantly 169 170 upregulated in BCNHL.

171

172 We detected AL512646.1 (also known as LOC100128906 and as a WDR45-like pseudogene) as 173 differentially expressed by B-cell non-Hodgkin's lymphoma samples, a novel observation which 174 was somewhat unexpected. Though AL512646.1 is annotated as a pseudogene, the RNA-175 sequencing data shows that it is downregulated in at least a subset of BCNHLs ($\log_2 FC = -15.1$), 176 and it has not been previously associated with cancer.

177

178 Next, we used the DRIMSeg algorithm to determine which genes had significant differences in 179 the presence of splice variants between case and control samples. This analysis returned 320 180 genes for which splice variants were significantly different (Table 4, S3 File). Apolipoprotein E 181 (APOE) was the most statistically significant splice variant (Lr [likelihood ratio] = 4470, # of 182 alternate splice variants = 4, adjusted p-value = 0). Specifically, we observed the expression of 183 APOE transcripts ENST0000252486, ENST00000425718, ENST00000434152, 184 ENST00000446996, and ENST00000485628 to significantly differ between non-Hodgkin's 185 lymphoma and non-diseased B-cells.

Table 4. Top 20 most significant splice variants (by gene). 186

Gene symbol	Ensembl ID	Lr*	# of Alternate Transcripts	Adjusted P- value
APOE	ENSG00000130203	4470	4	0
COL1A1	ENSG00000108821	1520	12	5.56×10^{-315}
COL27A1	ENSG00000196739	1060	7	6.71 × 10 ⁻²²⁰
RPL5	ENSG00000122406	1040	10	3.86×10^{-214}
KLF6	ENSG0000067082	961	6	7.41 × 10 ⁻²⁰¹
SRSF6	ENSG00000124193	954	5	1.56×10^{-200}
CYBRD1	ENSG0000071967	931	6	2.17 × 10 ⁻¹⁹⁴
PLEKHM1P1	ENSG00000214176	924	5	3.78×10^{-194}
VCP	ENSG00000165280	912	6	2.37×10^{-190}

DDX6	ENSG00000110367	872	7	8.01 × 10 ⁻¹⁸¹
THRAP3	ENSG0000054118	846	3	6.63×10^{-180}
FCGR2B	ENSG0000072694	771	4	1.75 × 10 ⁻¹⁶²
CHI3L1	ENSG00000133048	715	4	2.40×10^{-150}
IFITM3	ENSG00000142089	691	3	2.53×10^{-146}
ADAM28	ENSG0000042980	719	11	4.56×10^{-144}
CIB1	ENSG00000185043	662	2	2.04×10^{-141}
ZNF318	ENSG00000171467	645	3	1.88×10^{-136}
RPS28	ENSG0000233927	621	3	3.10×10^{-131}
CCDC124	ENSG0000007080	549	3	1.14 × 10 ⁻¹¹⁵
ZNF335	ENSG00000198026	545	3	8.02×10^{-115}

188 Significantly differentially expressed splice variants sorted by gene.

	189 *Lr = likelihood rat
--	--------------------------

190

We also observed that Collagen type I alpha 1 chain (COL1A1) had significant splice variants (Lr = 1520, # of alternate splice variants = 12, adjusted p-value = $5.55999999807983 \times 10^{-315}$). Interestingly, our study also found that the COL1A1 gene was significantly upregulated in BCNHL (logFC = 3.73, FDR = 9.78×10^{-48}). We also observed novel significant splice variants in Collagen type XXVII alpha 1 chain (COL27A1), which was found to be significant in BCNHL (Lr = 1060, # of alternate splice variants = 7, adjusted p-value = 6.71×10^{-220}).

197

198 We then wanted to determine which functional terms in the Gene Ontology were over-199 represented by the list of DEGs in BCNHL. The Camera algorithm checked 14,901 terms 200 (including gene ontologies and human phenotypes) for enrichment against the significant 201 differentially expressed genes that we generated with edgeR. Although there were 482 results (p-202 value < 0.05), none remained significant after multiple hypothesis correction (S4 File). The lack of 203 significant results is somewhat expected given the overall molecular heterogeneity of BCNHL 204 subtypes. To visualize the gene ontology changes, we used a hypergeometric enrichment 205 algorithm that applied a p-value cutoff of 0.05. We then averaged the edgeR fold-change values 206 for the genes of each gene ontology in the KEGG Brite hierarchy and plotted the enrichment 207 results using the R Treemap package to better understand the contribution of various terms to the 208 overall list of DEGs (Fig 3).

209

To better understand the results of our analysis at a more mechanistic level, we used the signaling pathway impact analysis (SPIA) algorithm to identify intracellular signaling pathways that play important roles in Lymphoma. This pathway analysis generates a null distribution through bootstrapping to identify pathways that are significantly modulated when comparing sets of samples. Our analysis revealed 33 significantly modulated pathways between lymphoma Bcells and non-diseased B-cells (Table 5, S5 File). Specifically, we observed eight pathways that

- were involved with the extracellular matrix and connective tissue in general, including Integrin signaling pathway, Extracellular matrix organization, ECM-receptor interaction, Focal adhesion, Integrins in angiogenesis, integrin signaling pathway, Collagen formation, and Collagen degradation. The upregulation of these pathways indicate that BCNHL likely benefits from modulations to the extracellular matrix.
- Table 5. Significant differentially modulated signaling pathways.
- 222

	Name	pSize	NDE	tA	pGFWER	Source Database
1	Integrin signalling pathway	99	86	114.394	2.39 × 10 ⁻⁵	Panther
2	Extracellular matrix organization	204	180	80.7398395	3.14 × 10 ⁻⁵	Reactome
3	ECM-receptor interaction	70	64	77.659	4.47 × 10 ⁻⁵	KEGG
4	Staphylococcus aureus infection	32	29	110.568396	0.000503428	KEGG
5	Complement and coagulation cascades	36	32	37.5461944	0.000674242	KEGG
6	Urokinase-type plasminogen activator	28	25	130.821315	0.000740169	NCI
	(uPA) and uPAR-mediated signaling					
7	Cytokine-cytokine receptor interaction	168	140	98.294	0.000780995	KEGG
8	Focal adhesion	182	150	236.615459	0.001133449	KEGG
9	PI3K-Akt signaling pathway	271	221	260.046197	0.001344307	KEGG
10	Complement cascade	29	27	102.278583	0.001440498	Reactome
11	Systemic lupus erythematosus	17	15	67.4577222	0.001616635	KEGG
12	b cell survival pathway	22	19	26.576	0.00167109	BioCarta
13	Small cell lung cancer	78	64	121.170067	0.001930414	KEGG
14	Integrins in angiogenesis	52	41	146.143424	0.00285984	NCI
15	Olfactory transduction	93	74	-148.8965	0.002966626	KEGG
16	integrin signaling pathway	37	29	77.0156667	0.003336442	BioCarta
17	erk and pi-3 kinase are necessary for	34	26	166.268917	0.003755165	BioCarta
	collagen binding in corneal epithelia					
18	RNA Polymerase I Promoter Clearance	85	72	-40.156	0.004307328	Reactome
19	Initial triggering of complement	15	14	44.508	0.004480759	Reactome
20	RNA Polymerase I Promoter Opening	39	34	-40.907	0.004675938	Reactome
21	RHO GTPases activate PKNs	67	57	39.779	0.004802382	Reactome
22	DNA Damage/Telomere Stress Induced Senescence	61	52	32.7708077	0.004980633	Reactome
23	Creation of C4 and C2 activators	7	7	27.365	0.005633091	Reactome
24	Collagen formation	66	63	26.4272897	0.006045837	Reactome
25	Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3	41	35	39.094	0.006675281	Reactome
26	MET activates PTK2 signaling	18	16	63.573	0.007079287	Reactome
27	Collagen degradation	17	15	131.8905	0.008037505	Reactome
28	MET promotes cell motility	28	24	97.5445	0.00808298	Reactome
29	Regulation of IGF Activity by IGFBP	11	10	25.958725	0.008404989	Reactome
30	Classical antibody-mediated complement activation	5	5	27.354	0.008619298	Reactome
31	Serotonin Neurotransmitter Release Cycle	11	9	-13.301889	0.015608196	Reactome
32	Class A/1 (Rhodopsin-like receptors)	81	77	5.908	0.026176599	Reactome
33	Peptide ligand-binding receptors	79	75	5.84	0.040928099	Reactome

223 The significantly differentially modulated pathway results. Included are nine extracellular matrix-

associated pathways.

*Abbreviations: psize = number of genes in pathway. NDE = number of genes from pathway
 which were differentially expressed. tA = measure of change between healthy and lymphoma
 expression; directionality indicates up- or down-regulation. pGFWER = p-value with adjustments
 appropriate to a multiplexed interaction network. (20)

- 229 230
- 231 We next used the Pathways2Targets algorithm to identify potentially novel drug targets for
- BCNHL from the signaling pathway results (S6 File). We sorted the results so that drug targets
- 233 present in multiple signaling pathways would be ranked higher (Table 6, S7 File). We predicted
- the most relevant existing FDA-approved drugs for other indications that could affect the
- 235 lymphoma phenotype are Doxycycline, Ocriplasmin, and Collagenase. We also identified ATN-
- 161 as a candidate drug, but it has only been tested in phase-two trials.

Table 6. Predicted BCNHL drugs based on signaling pathways.

	Drug Name	Drug ID	Significan t Pathways Targeted	Is FDA Approve d	Highes t Clinical Trial Phase	Has Been Withdrawn
1	OCRIPLASMIN	CHEMBL209522 2	13	TRUE	4	FALSE
2	ATN-161	CHEMBL429745 6	10	FALSE	2	FALSE
3	DOXYCYCLINE	CHEMBL120069 9	10	TRUE	4	FALSE
4	DOXYCYCLINE	CHEMBL1433	10	TRUE	4	FALSE
5	AS-1409	CHEMBL210941 3	9	FALSE	1	FALSE
6	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	CHEMBL210870 9	9	TRUE	4	FALSE
7	FIRATEGRAST	CHEMBL210496 7	9	FALSE	2	FALSE
8	L19IL2	CHEMBL210960 8	9	FALSE	3	FALSE
9	L19SIP 1311	CHEMBL210941 2	9	FALSE	2	FALSE
1 0	L19TNFA	CHEMBL210958 9	9	FALSE	2	FALSE
1 1	VOLOCIXIMAB	CHEMBL210806 1	9	FALSE	3	FALSE
1 2	ABITUZUMAB	CHEMBL210962 1	8	FALSE	2	FALSE
1 3	AL-78898A	CHEMBL459445 7	8	FALSE	2	FALSE
1	CILENGITIDE	CHEMBL429876	8	FALSE	3	FALSE

4						
1	EPTIFIBATIDE	CHEMBL1174	8	TRUE	4	FALSE
5						
1	ETARACIZUMAB	CHEMBL174301	8	FALSE	2	FALSE
6		4				
1	HUMAN C1-	CHEMBL429754	8	TRUE	4	FALSE
7	ESTERASE	9				
	INHIBITOR					
1	INTETUMUMAB	CHEMBL174303	8	FALSE	2	FALSE
8		2				
1	PEGCETACOPLA	CHEMBL429821	8	FALSE	3	FALSE
9	Ν	1				

The top 19 drug predictions for BCNHL. Included are several drugs currently in use and others that are novel candidates.

241

242 Rather than solely rely on the significant differential expression data to determine biomarkers, we 243 applied a more robust random forest machine learning method to predict biomarkers of BCNHLs. 244 Specifically, the DEG statistics focus on identifying genes that have a large difference in 245 expression between two states, while the random forest approach identifies genes that 246 consistently change across disease vs. healthy samples. Consequently, the random forest 247 approach identifies transcripts that are best capable of differentiating between disease and 248 healthy states. The top three genes identified by our random forest analysis included YES1, 249 FAM98B, and FERMT2 (Table 7, Figs 4A and 4B, S8 File). We then calculated the area under 250 the curve for the receiver-operator characteristic curve, which showed that when the expression 251 values from these three genes are combined they are 99.889% accurate at predicting whether 252 the patient samples had BCNHL (Fig 4C). 253 Figure 4. Biomarker Prediction Yields Three-Gene Signature with 99% Predictive Ability. 254 A) Biomarkers ranked by mean decrease in Gini impurity and permutation values using random 255 forest show YES1, FAM98B, and FERMT2 as the highest ranked predictive biomarkers (ranked 256 by mean decrease of Gini impurity score). B) Random forest biomarker prediction for the top

three genes in isolation. C) Receiver-operator characteristic curve using only YES1, FAM98B,
and FERMT2 shows these three genes are 99.889% accurate at predicting BCNHL status
(healthy or diseased).

260

261 Table 7. BCNHL biomarkers predicted from gene expression using machine learning

Gene Symbol	Mean Gini Decrease	edgeR Log ₂ Fold Change	edgeR False Discovery Rate	Disease Status	Mean (Read Counts)	Standard Deviation (Read Counts)	Median (Read Counts)
YES1	0.77	2.38	1.98x10 ⁻³⁸	Lymphoma	1151.756	1246.946	629
				Healthy	38.87234	66.01043	11
FAM98B	0.68	1.58	1.48x10 ⁻⁶⁰	Lymphoma	1797.452	1174.797	1456
				Healthy	248.4202	954.1375	32
FERMT2	0.67	2.83	1.46x10 ⁻³⁸	Lymphoma	1246.993	1200.669	841
				Healthy	32.46809	73.10299	4

262 263

The top three genes identified by our random forest biomarker prediction are high-fidelity biomarkers of BCNHL due to their consistent and extreme upregulation across our 134 clinical 264 BCNHL samples as compared to our 188 healthy B-cell samples. Presented above are statistics that capture the spread of transcriptional levels between BCNHL and healthy groups. 265

266 267

Discussion 268

269 The goal of this study was to collect publicly available RNA-seq data from GEO and process

270 those data to find differentially expressed genes, pathways, splice variants, and biomarkers. We

271 confirmed several biologically- and clinically relevant biomarkers and pathologic mechanisms that

272 were identified previously, as well as novel entities. We found several key genes that are

273 significantly differentially expressed in BCNHL including LUM and other SLRPs, complement

274 protein components, and the supposed pseudogene AL512646.1. We confirmed that previously

275 characterized biomarkers such as APOC1, VCAM1, CCL18, and CXCL9 are overexpressed in

276 BCNHL, and that 320 genes including APOE, COL1A1, and COL27A1 had differentially

277 expressed splice variants. We additionally found a BCNHL reliance on the upregulation of

278 pathways associated with the extracellular matrix.

279

280 To our knowledge, this is the largest meta-analysis of human samples in the BCNHL field to-date.

281 While some may be concerned that the signals from the individual subtypes of non-Hodgkin's B-

282 cell lymphomas could drown one another out, we believe that including representative samples

283 from multiple BCNHL subtypes augments the signal(s) that are shared among the represented

284 subtypes and could aid in the identification of shared mechanistic insights with reduced bias. One

285 potential limitation of our study was to only evaluate samples from the GEO database for

inclusion in our analysis. Our intentional focus on BCNHL excluded multiple myelomas, B-cell
leukemias, or Hodgkin's B-cell lymphomas. Promising future directions may include mining
additional public databases for similar data and potentially expanding the scope of any future
meta-analysis to include all B-cell malignancies. In addition, it is possible that our focus on
incorporating multiple publicly available datasets may have introduced potential biases in patient
age, gender, or ethnicity.

292

293 Though there is evidence in the literature that directly associate BCNHL to some of our results 294 (e.g. genes, splice variants, and pathways), some of our findings are novel to BCNHL. In cases 295 where no previously published research indicates the relationship between BCNHL and our results, we will appeal to the Hallmarks of Cancer to investigate the relationship between our 296 297 differentially expressed result and a distinct cancer system (4). We therefore ranked both the 298 accuracy and confidence in our results by their relevance to BCNHL, followed by B-cell cancers in 299 general, all blood cancers, and finally all cancers. We believe that identifying a possible 300 mechanism for a gene that is associated with other cancers, and unresearched in BCNHL is still 301 relevant. We expect that a subset of these findings will justify additional wet lab experimentation. 302

Differentially expressed genes suggest shared underlying

304 mechanisms for lymphomas

LUM seems to play a role in the progression or non-progression of several different cancer types. Mahadevan *et al.* previously reported upregulated LUM in both T- and B-cell lymphomas, but offered no insights on potential mechanisms (21). A literature search of parallel systems revealed that in breast cancer, high stromal-cell expression of LUM adjacent to the tumor stalls tumor growth, and lowered stromal expression of LUM correlates with higher breast cancer mortality rates and increased severity (22). In melanoma, LUM in the extracellular matrix halts metastasis through direct interaction with alpha-2-beta-1 integrin (23). Both breast cancer and pancreatic

cancer cells have been documented to upregulate LUM, along with many other cancer types (19).
Overall, LUM expression by cancer cells seems to correlate with more aggressive cancers and
poorer patient outcomes. The massive LUM upregulation illustrated in our samples may be due to
the fact that the BCNHL samples available on GEO were mostly from advanced or refractory
cases of BCNHL. The prior finding that high LUM expression around tumors is protective against
metastasis in several cancer subtypes indicates the potential for LUM as a cancer-stalling
therapy.

319

320 Interestingly, a subset of the members in the SLRP protein family have been previously identified 321 in B-cell Non-Hodgkin's lymphomas including DCN (24), BGN (24), ASPN (25), FMOD (26), LUM 322 (21), PRELP (26), and TSKU (27). However, other members within the SLRP family have not 323 been previously considered as lymphoma biomarkers or potential pathology-inducing molecules. 324 Our novel finding is that the SLRPs ECM2, CHAD, PODN, and PODNL1 are differentially 325 expressed in BCNHL. Proteoglycans have been shown to be associated with pro-cancer 326 mechanisms in prostate, breast, colon, lung, ovary, mesothelium, pancreatic, lymphoma, and 327 esophageal cancers (19). Our results show two upregulated pathways in BCNHL that were 328 previously shown to be mechanistically intertwined with proteoglycans in cancer, which are the 329 Focal Adhesion pathway (28) and the PI3K-Akt signaling pathway (29). Taken together, this may 330 suggest a connection between previously established proteoglycan cancer mechanisms and B-331 cell non-Hodgkin's lymphomas. Additional work is still required to elucidate the role(s) that these 332 entities play in BCNHL.

333

In the context of other cancers, increased expression of complement genes C1QA and C1QB at week 16 of mantle cell lymphoma treatment by Venetoclax and Ibrutinib was significantly associated with a worse prognosis (30), illustrating that C1QA and C1QB may be associated with resistance to cancer drugs. Jiang et al. showed via immunohistochemistry that C1QB localizes to the nuclei of gastric cancer cells (31). C1QB's nuclear localization suggests that C1QB may have

additional function(s). Upregulation of C1QA, C1QB, and C1QC in peripheral T-cell lymphoma
(32) and upregulation of C1QC in Epstein-Barr Virus-positive diffuse large B-cell lymphoma (33)
have been reported previously. In other in-vitro and in-vivo cancer models, the whole C1q protein
has been shown to mediate metastasis, motility, growth and proliferation, and adhesion (34). Our
results add to the growing body of work suggesting a potential alternate function of complement
proteins in cancer that warrants further investigation.

345

In addition to our novel findings on differentially expressed genes, we were also able to detect

347 statistically significant genes that were previously characterized in at least one subtype of

348 BCNHL. The first of these proteins is Apolipoprotein C1 (APOC1), which we observed to be

349 upregulated in BCNHL. APOC1 is one of three genes whose expression levels are predictive of

diffuse large B-cell lymphoma severity (35), and it is also upregulated in late stage lung cancers

- as compared to early stage lung cancers (36). This suggests that APOC1 may be contributing to
- 352 cancer pathology across diverse cancers in multiple cell types.
- 353

Our observation that C-C motif chemokine ligand 18 (CCL18), which has a well-recognized role in lymphoma, was upregulated in our BCNHL analysis is relevant since this gene assists large Bcell lymphoma in cell proliferation, the NF-Kappa-B pathway, and the PI3K-AKT pathway (37). Its upregulation in macrophages and dendritic cells from cutaneous T-cell lymphoma lesions was associated with a negative prognosis (38).

359

Our finding C-X-C motif chemokine ligand 9 (CXCL9) to be significantly upregulated in our analysis of B-cells is interesting since this gene has been shown to promote the progression of diffuse large B-cell lymphoma by halting degradation of beta-catenin (CTNNB1) and upregulating its initial expression (39). Our findings support this proposed mechanism with CTNNB1 being upregulated in lymphoma ($log_2FC = 1.1$, FDR = 1.54×10^{-33}), while other elements of the CTNNB1 "destruction complex" were mostly downregulated. Specifically, several of the known

366 components of the destruction complex that were detected in our analysis include APC ($\log_2 FC =$

-0.755, FDR = 3.51×10^{-11}), GSK3B (log₂FC = -0.692, FDR = 2.62×10^{-3}), CSNK1A1 (not

significant), AXIN1 (log₂FC = 0.533, FDR = 3.96×10^{-10}), BTRC (not significant), and FBW11

369 $(\log_2 FC = -0.692, FDR = 5.60 \times 10^{-20}).$

370

371 We identified several other genes of that may be relevant to pathogenesis. Small but significant 372 upregulation of AXIN1 is of interest for additional investigation due to its ties to CXCL9, and is not 373 known to have multiple heterogenous functions (40). AXIN1 regulates the Wnt and JNK signaling 374 pathways (41), and it regulates the Wnt pathway by degrading CTNNB1 (39). If CTNNB1 isn't 375 degraded by AXIN1, CTNNB1 translocates to the nucleus and interacts with LEF1, which we 376 found to be significantly upregulated, and TCF7 (not significant in this study), causing 377 transcription of Wnt pathway target genes to occur (42,43). Wnt helps to regulate cell cycle and 378 contributes to the increased growth rate of many cancer types (44). AXIN1 activates the JNK 379 signaling pathway by binding to MAP3K1, which we found to be significantly downregulated, or to 380 MAP3K4, which was significantly upregulated (45). Since CTNNB1 has been shown to contribute 381 to apoptosis resistance in multiple myeloma cells (46), it is possible that the inability to stop the 382 destruction of CTNNB1 in lymphoma may share a similar mechanism. 383 384 Finally, VCAM1 upregulation is associated with a poor prognosis for patients with non-Hodgkin's 385 lymphomas, and VCAM1 is under investigation as a potential serum biomarker for assessing

disease progression (47). Adhesion molecules such as VCAM1 promote cancer metastasis, or in

the case of blood cancers, extravasation, by allowing cancer cells to exit the bloodstream and

integrate with healthy tissues throughout the body (48).

389

390 Splice variants suggest relevance to lymphomas

391 To better understand the contribution of differentially expressed splice variants to disease, we

392 examined the highest-ranked DRIMseq results. This algorithm calculates statistical significance

393 based on the number of reads mapped to exons that are present in each splice variant. Our 394 observation that Apolipoprotein E (APOE) was the highest-ranking splice variant result validates 395 previous findings that associate this gene with pancreatic cancer pathology (49). In addition, 396 pediatric patients with malignant lymphoma and acute lymphoblastic leukemia who express 397 isoforms E3 and E4 of APOE are at higher risk of developing extreme hypertriglyceridemia (50). 398 Though little research has been done concerning the mechanisms of APOE in BCNHL, we 399 believe that APOE may be contributing to disease by participating in the Regulation of Insulin-like 400 Growth Factor (IGF) activity by Insulin-like Growth Factor Binding Protein (IGFBP) pathway, 401 which is we found to be a significantly modulated pathway that includes APOE. The significance 402 of APOC1 as a DEG in BCNHL, paired with the evidence of significant APOE splice variants 403 suggest that apolipoproteins may be useful targets for future BCNHL treatments. 404 405 Our observation of Collagen type I alpha 1 chain (COL1A1) as a highly ranked splice variant 406 result is novel to the best of our knowledge. However, the literature indicates that the COLA1A-407 014 transcript regulates the CXCL12-CXCR4 axis in gastric cancer, leading to tumor progression 408 (46). In addition to displaying significant differences in splice variant expression, we also found 409 COL1A1 to be significantly upregulated in BCNHL. COL1A1 has previously been reported to be 410 upregulated in peripheral T-cell lymphoma (21). In Hodgkin's lymphoma, COL1A1 overexpression 411 is associated with epigenetic silencing of the RNA demethylase ALKBH3 and reduced survival 412 (51). COL1A1 is a member of several of our significant upregulated pathways involving the 413 extracellular matrix (ECM-receptor interaction, Focal adhesion, Extracellular matrix organization, 414 and Collagen formation). This involvement in extracellular matrix-related pathways strengthens 415 the case that the mechanism of COL1A1 may involve tumor cell interaction with its outer 416 environment. 417

Collagen type XXVII alpha 1 chain (COL27A1) having significant changes among its expressed
 splice variants in BCNHL is interesting since it was recently reported as being overexpressed in

	420	adenoid cystic carcinoma	52). Like COL1A1, COL27A1 is a member of the upregula	ated
--	-----	--------------------------	---	------

- 421 Extracellular matrix organization and Collagen formation pathways, suggesting that COL27A1
- 422 could play a role in BCNHL extravasation.
- 423

424 Extracellular matrix-related pathways may contribute to disease

425 Our signaling pathway enrichment analysis broadened the scope of our analysis and 426 interpretation. Many of our findings supported an interesting reliance of BCNHL on pathways 427 associated with the extracellular matrix. Recent research has suggested the importance of 428 extracellular matrix components in reactivating quiescent cancer cells through the β1-integrin 429 signaling pathway (53). It would follow that interaction with extracellular matrix components also 430 plays a role in regulating cancer cells. To our knowledge, no studies have reported the integrin 431 signaling pathway to be activated in BCNHL, though it has been reported as activated in the 432 closely-related cancer NK/T-cell lymphoma (21). The activation of these pathways suggests that 433 malignant BCNHL cells may have an advantage by interacting with the extracellular matrix. Such 434 interactions with the extracellular matrix are typically considered to be an important part of 435 metastasis (48). We found this result to be interesting since lymphomas are liquid tumors, 436 unbound by extracellular matrix. This upregulation of pathways allowing interaction with the 437 extracellular matrix may suggest that BCNHL could be invading non-lymphatic and/or non-438 circulatory tissues. 439

The trend of extracellular matrix interaction is also seen in the DEG results, adding support to the
idea that interaction with the extracellular matrix is important for BCNHL growth and survival.
Additionally, COL1A1 and COL27A1, which are members of extracellular matrix-related
pathways, are two of the genes with the most significantly differential expression of splice

444 variants.

445

446 **Drug prediction algorithm returned both tested and novel**

447 candidates

448 Of our top drug results, doxycycline is currently in use for ocular B-cell lymphomas (54,55). It is 449 additionally under investigation for diffuse large B-cell lymphoma; recent work found doxycycline 450 suppresses diffuse large B-cell lymphoma growth in vitro and in vivo via CSN5 inhibition (56). 451 ATN-161 is a novel drug candidate for BCNHL. Though it is only in phase two of clinical trials, it 452 has been a successful drug against refractory solid tumors, making it a promising drug candidate 453 for other susceptible malignancies (57). ATN-161 suppresses cancer via integrin beta1 alpha5 454 antagonism, disabling invasion and metastasis (58). Ocriplasmin reverses vitreomacular 455 adhesion via interaction with fibronectin and laminin (59). Though ocriplasmin has never been 456 used in cancer before, it may be a promising drug candidate due to its ability to modulate 457 adhesion. Collagenase clostridium histolyticum is under investigation for treating collagen-rich 458 uterine fibroids and was successful at reducing the stiffness of the tumors (60).

459

460 Machine learning predicts novel biomarkers of BCNHL

461 YES1, FERMT2, and FAM98B are novel biomarkers not previously associated with BCNHL. 462 However, each has well-documented cancer associations. YES1 is a tyrosine kinase which 463 regulates cell cycle and apoptosis in vitro and cell growth in vivo of tumors with YES1 464 amplification (61). YES1 has been previously identified as a biomarker for non-small cell lung 465 cancer and esophageal adenocarcinoma (62,63) and may be a potential membrane biomarker. 466 YES1 can anchor to the inner membrane with help from peptide SMIM30 (64), but whether it can 467 flip to the outer leaflet has not been investigated. The role of YES1 in BCNHL pathogenesis also 468 needs additional investigation. FERMT2 has previously been pinpointed as a biomarker for other 469 cancers previously including non-small cell lung cancer and prostate cancer (65,66), but not for 470 BCNHL. FERMT2 stabilizes CTNNB1, which is a well-documented activator of oncogene 471 transcription, and is implicated in Wnt pathway regulation (67). Additionally, FERMT2 enhances

472	integrin signaling and mediates migration, invasion, and focal adhesion (68,69). Though FAM98B
473	has been shown to play an important role in the development of multiple cancers, it has not
474	previously been identified as a biomarker for any cancer. FAM98B is an arginine
475	methyltransferase, is utilized in tumorigenesis, and works in tandem with DDX1, a pan-cancer
476	marker, in RNA metabolism/processing (70,71). Like YES1 and FERMT2, FAM98B has not been
477	previously identified as a biomarker for BCNHL. These three genes have substantial diagnostic
478	potential as a liquid biopsy that could be generalizable across B-cell non-Hodgkin's lymphoma
479	subtypes. Further validation is needed to determine whether these are suitable biomarkers for
480	diagnostic or screening application.

481

482

483 In summary, our meta-analysis identified many significant DEGs and pathways that play a role in 484 B-cell non-Hodgkin's lymphomas. Our findings confirm results of previous BCNHL research, 485 indicating that the statistical analyses applied within our computational workflow pipeline are 486 effective at accurately identifying statistically significant genes, splice variants, and pathways with 487 clinical and pathological relevance. Additionally, several of our results are novel, which need 488 additional validation in future experiments. It is likely that at least some of these novel findings 489 were detected due to the ability of our meta-analysis to reduce the statistical "noise" produced by 490 outliers from individual studies and increase the biologically-relevant signal. Specifically, our 491 findings suggest that LUM and 10 other small leucine-rich proteoglycans are significantly 492 differentially expressed in BCNHL, that AL512646.1 is not a pseudo-gene, that APOE, COL1A1, 493 and COL27a1 have significant differentially expressed splice variants in BCNHL, and that BCNHL 494 is strongly reliant on the overexpression of extracellular matrix-associated pathways. The 495 predominant drug prediction results nearly universally targeted extracellular matrix-associated 496 mechanisms, and has yielded several promising new potential drug candidates including 497 ocriplasmin and ATN-161. Our random forest biomarker discovery pinpointed three novel 498 biomarker genes not previously associated with BCNHL, YES1, FERMT2, and FAM98B, which

499	show high fidelity in predicting lymphoma presence based on transcriptional levels.	These
-----	---	-------

500 findings shed additional light on the underlying intracellular mechanisms of BCNHL and could be

501 used in the development of improved diagnostics and therapeutics to further improve human

- 502 health.
- 503
- 504

505 **Methods**

506 **Collecting samples**

507 RNA-sequencing samples were acquired from the National Center for Biotechnology Information 508 (NCBI) Gene Expression Omnibus (GEO) database using the search term, "b-cell lymphoma" to 509 find B-cell non-Hodgkin's lymphoma samples and healthy B-cell controls. The automatic GEO 510 filters "Homo sapiens" and "high-throughput RNA-sequencing" were applied. Cell lines, formalin-511 fixed paraffin-embedded tissues, gene expression microarray experiments, single-cell (10X) 512 RNA-sequencing experiments, xenografts, samples known to be infected with EBV and KSHV. 513 and samples which contained more diverse cell types (i.e., whole blood, lymph node, PBMCs, 514 brain, etc.) were manually excluded. All samples that had one or more of these disqualifying 515 attributes were excluded from the dataset prior to analysis, which may have included only a 516 subset of samples from any individual study in the meta-analysis. Multiple myeloma, leukemia, 517 and Hodgkin's lymphoma samples were intentionally excluded in favor of focusing on B-cell non-518 Hodgkin's lymphomas. Records were accepted or rejected based on the standardized exclusion 519 criteria detailed above by our team. To avoid inclusion bias, any sample that could not be 520 excluded by the standardized exclusion criteria was included in the study. While a subset of the 521 healthy control samples was obtained from the same RNA sequencing projects as the BCNHL 522 samples, others were obtained from three unrelated B-cell datasets with healthy controls to 523 create roughly equivalent-sized BCNHL and healthy groups. Final dataset assembly from GEO 524 concluded on October 22, 2020, resulting in a dataset of 322 samples (134 BCNHL samples and

525 188 healthy B-cell controls) from ten studies (7–18). The raw data for these experiments were 526 previously collected by the data providers and conform to the appropriate ethical oversight to 527 protect patient autonomy and patient identity. All 10 primary RNA-sequencing datasets from 528 which samples were gathered for our lymphoma meta-analysis have been published in the peer-529 reviewed literature, increasing overall confidence that each dataset has acceptable quality (Table 530 1, Fig 1).

531

532 Preprocessing of RNA-sequencing data

533 Following the manual curation of the RNA-seq samples, the fastq files were pre-processed as 534 previously described (72). In brief, fastg files containing RNA-sequencing data were downloaded 535 from the Sequence Read Archive (SRA) using the sratools software package. The fastq files, the 536 associated metadata file, and a configuration file for each dataset were then generated and used 537 as input to the Automated Reproducible MOdular Workflow for Preprocessing and Differential 538 Analysis of RNA-seq Data (ARMOR) workflow (73). A configuration file was used by ARMOR to 539 appropriately set up a python-based Snakemake workflow (74). In the ARMOR workflow, 540 adapters and poor-quality regions of reads were trimmed with TrimGalore! (75), quality control 541 metrics were calculated with FastQC (76), reads were mapped to the human GRCh38 542 transcriptome and total gene transcripts quantified with Salmon (77), significant differential gene 543 expression was calculated using a negative binomial distribution implemented in edgeR (78), 544 Gene Ontology enrichment was performed against terms from the MSigDB (79) while adjusting 545 for inter-gene correlation using the Camera algorithm (80), and significant splice variants were 546 predicted with DRIMseq (81). The significant differentially expressed genes from the ARMOR 547 workflow were then used as input to the signaling pathway impact analysis (SPIA) algorithm to 548 enrich differentially expressed genes against intracellular signaling pathways from five databases 549 including KEGG, Panther, BioCarta, Reactome, and NCI (20,82–85). Differentially expressed 550 genes and splice variants calculated by ARMOR and DRIMSeq were evaluated by the effect

- 551 measures log2 fold change and likelihood ratio respectively. Confidence in results was
- 552 accomplished using false discovery-rate adjusted p-values.
- 553

554 Additional analysis and visualization of differentially expressed

555 genes and gene ontologies

- 556 The PRISMA flowchart template was used to generate figure one consistent with transparent
- 557 reporting of meta-analysis generation and results (86).
- 558
- 559 The R package ggplot was used to construct the Fig 2 volcano plot from using FDRs and log2
- 560 fold change values for each gene from the edgeR output (87).
- 561

562 The KEGG ontology was extracted from the Brite Hierarchy using existing code (82). Genes

563 included in the Brite Hierarchy were then computationally matched to their corresponding edgeR

log₂ fold change values. A statistical enrichment of the KEGG gene ontologies was performed

using the R package bc3net (88) prior to visualizing the bc3net enrichment results with the R

566 package Treemap in Fig 3 (89).

567

568 Biomarker prediction using differentially expressed gene data

569 Salmon-derived transcript counts were organized into a tabular format and samples were

570 randomly assigned to either the testing set (30%) or the training set (70%). The R package

571 randomForest was used to run a supervised classification analysis to determine biomarkers (90).

- 572 The initial results from the whole transcriptome were then reduced to the 3, 5, and 10 best-
- 573 scoring transcriptional biomarkers, based on the mean Gini impurity decrease values for each of
- 574 the features. These values were then sorted by size to determine the transcribed genes from the
- 575 original dataset with the largest association. The area under the curve (AUC) was calculated from

- 576 the receiver operator characteristic curves that were generated for each set of random forest
- 577 results to determine the efficacy of the selected biomarkers for disease prediction.
- 578

579 Drug prediction using differentially modulated pathways

- 580 Drug prediction was conducted by running the significantly modulated pathways file that was
- 581 generated by SPIA file through Pathways2Targets2.R algorithm (91). To summarize drug
- 582 findings, the Pathways2Targets output was processed using a custom R script
- 583 most_common_treatments_2021_09_19.R (92).
- 584

585 Other information

- 586 This meta-analysis was not registered. The review protocol was not prepared separately but is
- 587 described in detail in the methods section. This meta-analysis received no specific financial
- 588 support and was supported by general funding from Brigham Young University. Brigham Young
- 589 University played no role in the ideation, synthesis, or analysis of this transcriptomic meta-
- analysis. The authors each declare that they have no competing interests. All raw data analyzed
- 591 in this study can be found in NCBI's GEO. Analytical codes can be found as cited in materials and
- 592 methods. All processed data are available in the supplementary materials or at DOI:
- 593 10.5281/zenodo.4757764.
- 594

595 Acknowledgments

We thank the high-performance computing resources hosted by the BYU Research Computing
Center. We also gratefully acknowledge those who generated, provided, and submitted the
original data.

599

600

601 **References**

- Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer
 Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted
 Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden
 of Disease Study. JAMA Oncology. 2018 Nov 1;4(11):1553–68.
- 6072.Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. The Lancet. 2012 Sep6081;380(9844):848–57.
- Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005
 Apr;5(4):251–62.
- 4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70.
- 6125.Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res. 2017;7(5):1016–61336.
- 6. Ochoa D, Hercules A, Carmona M, Suveges D, Gonzalez-Uriarte A, Malangone C, et al.
 615 Open Targets Platform: supporting systematic drug-target identification and prioritisation.
 616 Nucleic Acids Res. 2021 Jan 8;49(D1):D1302–10.
- Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, et al. Tumor Microenvironment
 Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients
 with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020
 Sep 15;26(18):4823–31.
- 6218.Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, et al. Non-oncogene Addiction to622SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell. 2019 Jun 10;35(6):916-931.e9.
- 9. Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, et
 al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor
 therapy. Blood. 2018 Aug 16;132(7):694–706.
- Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, et al. AICDA drives
 epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nat
 Commun. 2018 Jan 15;9(1):222.
- Raju S, Kretzmer LZ, Koues OI, Payton JE, Oltz EM, Cashen A, et al. NKG2D-NKG2D Ligand
 Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In
 Vivo. J Immunol. 2016 Jun 1;196(11):4805–13.
- Koues OI, Kowalewski RA, Chang LW, Pyfrom SC, Schmidt JA, Luo H, et al. Enhancer
 sequence variants and transcription-factor deregulation synergize to construct pathogenic
 regulatory circuits in B-cell lymphoma. Immunity. 2015 Jan 20;42(1):186–98.

Rouhigharabaei L, Finalet Ferreiro J, Tousseyn T, van der Krogt JA, Put N, Haralambieva E,
et al. Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of
N-truncated isoforms of FOXP1. PLoS One. 2014;9(1):e85851.

- Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, et al. EZH2 is required for
 germinal center formation and somatic EZH2 mutations promote lymphoid
 transformation. Cancer Cell. 2013 May 13;23(5):677–92.
- Verma A, Jiang Y, Du W, Fairchild L, Melnick A, Elemento O. Transcriptome sequencing
 reveals thousands of novel long non-coding RNAs in B cell lymphoma. Genome Med. 2015
 Nov 1;7:110.
- 16. Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct
 Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic
 Responses in Systemic Lupus Erythematosus. Immunity. 2018 Oct 16;49(4):725-739.e6.
- 547 17. Scharer CD, Blalock EL, Mi T, Barwick BG, Jenks SA, Deguchi T, et al. Epigenetic
 548 programming underpins B cell dysfunction in human SLE. Nat Immunol. 2019
 649 Aug;20(8):1071–82.
- Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, et al. IL-21 drives expansion and
 plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE. Nat Commun. 2018
 May 1;9(1):1758.
- Appunni S, Anand V, Khandelwal M, Gupta N, Rubens M, Sharma A. Small Leucine Rich
 Proteoglycans (decorin, biglycan and lumican) in cancer. Clin Chim Acta. 2019 Apr;491:1–7.
- 65520.Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, et al. A novel signaling pathway656impact analysis. Bioinformatics. 2009 Jan 1;25(1):75–82.
- Mahadevan D, Spier C, Croce KD, Miller S, George B, Riley CJ, et al. Gene Expression
 Profiling of Peripheral T-Cell Lymphoma (PTCL, NOS) and Comparison to Diffuse Large BCell Lymphoma (DLBCL). Blood. 2004 Nov 16;104(11):2277–2277.
- Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. Reduced
 Expression of the Small Leucine-rich Proteoglycans, Lumican, and Decorin Is Associated
 with Poor Outcome in Node-negative Invasive Breast Cancer. Clin Cancer Res. 2003 Jan
 1;9(1):207–14.
- Brézillon S, Pietraszek K, Maquart FX, Wegrowski Y. Lumican effects in the control of
 tumour progression and their links with metalloproteinases and integrins. FEBS J. 2013
 May;280(10):2369–81.
- Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, et al. Clinical
 and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.
 Cancer Discov. 2021 Jun 1;11(6):1468–89.

670 25. Sarkozy C, Chong L, Takata K, Chavez EA, Miyata-Takata T, Duns G, et al. Gene expression 671 profiling of gray zone lymphoma. Blood Advances. 2020 Jun 9;4(11):2523–35. 672 26. Mikaelsson E, Jeddi-Tehrani M, ÖSterborg A, Shokri F, Rabbani H, Mellstedt H. Small 673 Leucine Rich Proteoglycans as Novel Tumor Markers In Chronic Lymphocytic Leukemia. 674 Blood. 2010 Nov 19;116(21):694. 675 27. Huang H, Zhang D, Fu J, Zhao L, Li D, Sun H, et al. Tsukushi is a novel prognostic biomarker 676 and correlates with tumor-infiltrating B cells in non-small cell lung cancer. Aging (Albany 677 NY). 2021 Jan 10;13(3):4428–51. 678 28. Munesue S, Kusano Y, Oguri K, Itano N, Yoshitomi Y, Nakanishi H, et al. The role of 679 syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-680 derived metastatic clones. Biochem J. 2002 Apr 15;363(Pt 2):201-9. 681 29. Mahtouk K, Tjin EPM, Spaargaren M, Pals ST. The HGF/MET pathway as target for the 682 treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta. 2010 683 Dec;1806(2):208-19. 684 Davis J, Handunnetti SM, Sharpe C, Turner G, Anderson MA, Roberts AW, et al. Long Term 30. 685 Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with 686 Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers. Blood. 2019 687 Nov 13;134(Supplement 1):2791-2791. 688 Jiang J, Ding Y, Wu M, Lyu X, Wang H, Chen Y, et al. Identification of TYROBP and C1QB as 31. 689 Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis. Front 690 Oncol. 2020;10:1765. 691 Gao HX, Wang MB, Li SJ, Niu J, Xue J, Li J, et al. Identification of Hub Genes and Key 32. Pathways Associated with Peripheral T-cell Lymphoma. Curr Med Sci. 2020 Oct;40(5):885-692 693 99. 694 33. Yoon H, Park S, Ju H, Ha SY, Sohn I, Jo J, et al. Integrated copy number and gene expression 695 profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma. Genes 696 Chromosomes Cancer. 2015 Jun;54(6):383-96. 697 34. Bulla R, Tripodo C, Rami D, Ling GS, Agostinis C, Guarnotta C, et al. C1q acts in the tumour 698 microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. 2016 Feb 1;7(1):10346. 699 700 Zamani-Ahmadmahmudi M, Nassiri SM. Development of a Reproducible Prognostic Gene 35. Signature to Predict the Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma. 701 702 Sci Rep. 2019 Aug 21;9(1):12198. 703 Ko HL, Wang YS, Fong WL, Chi MS, Chi KH, Kao SJ. Apolipoprotein C1 (APOC1) as a novel 36. 704 diagnostic and prognostic biomarker for lung cancer: A marker phase I trial. Thorac Cancer. 705 2014 Nov;5(6):500-8.

706 707	37.	Zhou Q, Huang L, Gu Y, Lu H, Feng Z. The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research. Cancer Biomark. 2018;21(4):925–34.
708 709 710	38.	Miyagaki T, Sugaya M, Suga H, Ohmatsu H, Fujita H, Asano Y, et al. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis. J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e60-67.
711 712 713	39.	Ruiduo C, Ying D, Qiwei W. CXCL9 promotes the progression of diffuse large B-cell lymphoma through up-regulating β -catenin. Biomedicine & Pharmacotherapy. 2018 Nov 1;107:689–95.
714 715 716	40.	Mani M, Chen C, Amblee V, Liu H, Mathur T, Zwicke G, et al. MoonProt: a database for proteins that are known to moonlight. Nucleic Acids Research. 2015 Jan 28;43(D1):D277– 82.
717 718 719	41.	Kusano S, Raab-Traub N. I-mfa domain proteins interact with Axin and affect its regulation of the Wnt and c-Jun N-terminal kinase signaling pathways. Mol Cell Biol. 2002 Sep;22(18):6393–405.
720 721	42.	Bienz M. TCF: transcriptional activator or repressor? Current Opinion in Cell Biology. 1998 Jun 1;10(3):366–72.
722 723	43.	Escobar G, Mangani D, Anderson AC. T cell factor 1: A master regulator of the T cell response in disease. Sci Immunol. 2020 Nov 6;5(53):eabb9726.
724 725	44.	Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2021 Jan;21(1):5–21.
726 727 728	45.	Luo W, Ng WW, Jin LH, Ye Z, Han J, Lin SC. Axin Utilizes Distinct Regions for Competitive MEKK1 and MEKK4 Binding and JNK Activation *. Journal of Biological Chemistry. 2003 Sep 26;278(39):37451–8.
729 730	46.	Su N, Wang P, Li Y. Role of Wnt/β-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells. Oncol Lett. 2016 Dec;12(6):4623–9.
731 732 733 734	47.	Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, et al. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2012 Jan;53(1):50–6.
735 736	48.	Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993 Aug;4(4):219– 29.
737 738 739	49.	Omenn GS, Yocum AK, Menon R. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Dis Markers. 2010;28(4):241–51.

- Tozuka M, Yamauchi K, Hidaka H, Nakabayashi T, Okumura N, Katsuyama T.
 Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute
 lymphoblastic leukemia and malignant lymphoma. Ann Clin Lab Sci. 1997 Sep 1;27(5):351–
 7.
- 51. Esteve-Puig R, Climent F, Piñeyro D, Domingo-Domènech E, Davalos V, Encuentra M, et al.
 Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen,
 conferring poor clinical outcome. Blood. 2021 Feb 18;137(7):994–9.
- 52. Arolt C, Meyer M, Hoffmann F, Wagener-Ryczek S, Schwarz D, Nachtsheim L, et al.
 Expression Profiling of Extracellular Matrix Genes Reveals Global and Entity-Specific
 Characteristics in Adenoid Cystic, Mucoepidermoid and Salivary Duct Carcinomas. Cancers.
 2020 Sep;12(9):2466.
- 53. Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS, et al. Metastatic growth
 from dormant cells induced by a col-l-enriched fibrotic environment. Cancer Res. 2010 Jul
 15;70(14):5706–16.
- 54. Kim TM, Kim KH, Lee MJ, Jeon YK, Lee SH, Kim DW, et al. First-line therapy with doxycycline
 in ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective analysis
 of clinical predictors. Cancer Science. 2010;101(5):1199–203.
- 55. Han JJ, Kim TM, Jeon YK, Kim MK, Khwarg SI, Kim CW, et al. Long-term outcomes of firstline treatment with doxycycline in patients with previously untreated ocular adnexal
 marginal zone B cell lymphoma. Ann Hematol. 2015 Apr 1;94(4):575–81.
- Fulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, et al. Inhibition of COP9signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell
 lymphomas by doxycycline. Oncotarget. 2015 Jun 4;6(17):14796–813.
- 57. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, et al. Phase 1 trial of
 the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in
 patients with solid tumours. Br J Cancer. 2006 Jun;94(11):1621–6.
- 58. Barkan D, Chambers AF. β1-Integrin: A Potential Therapeutic Target in the Battle against
 Cancer Recurrence. Clinical Cancer Research. 2011 Nov 30;17(23):7219–23.
- 59. Baldo BA. Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse
 Effects. BioDrugs. 2015 Feb 1;29(1):31–55.
- Jayes FL, Liu B, Moutos FT, Kuchibhatla M, Guilak F, Leppert PC. Loss of stiffness in
 collagen-rich uterine fibroids after digestion with purified collagenase Clostridium
 histolyticum. American Journal of Obstetrics and Gynecology. 2016 Nov 1;215(5):596.e1596.e8.

Hamanaka N, Nakanishi Y, Mizuno T, Horiguchi-Takei K, Akiyama N, Tanimura H, et al. YES1
Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification. Cancer Research.
2019 Nov 15;79(22):5734–45.

62. Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, et al. YES1 Drives
Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Am J Respir Crit
Care Med. 2019 Oct;200(7):888–99.


- 53. Liu Z, Jiang F, Tian G, Wang S, Sato F, Meltzer SJ, et al. Sparse Logistic Regression with Lp
 Penalty for Biomarker Identification. Statistical Applications in Genetics and Molecular
 Biology [Internet]. 2007 Feb 10 [cited 2022 Apr 16];6(1). Available from: http://www.degruyter.com/document/doi/10.2202/1544-6115.1248/html
- Pang Y, Liu Z, Han H, Wang B, Li W, Mao C, et al. Peptide SMIM30 promotes HCC
 development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation.
 Journal of Hepatology. 2020 Nov 1;73(5):1155–69.
- 5. Sun W, Guo J, Cheng Z, Zhang Y, Gao Y. Identification of the Dysregulated Pathways and Key Gene in Prostate Cancer by Transcriptome Analysis and Cell Biology Experiments
 [Internet]. In Review; 2022 Jan [cited 2022 Apr 16]. Available from: https://www.researchsquare.com/article/rs-1122595/v1
- 50. Su X, Liu N, Wu W, Zhu Z, Xu Y, He F, et al. Comprehensive analysis of prognostic value and
 immune infiltration of kindlin family members in non-small cell lung cancer. BMC Med
 Genomics. 2021 May 2;14(1):119.
- 794 67. Yu Y, Wu J, Wang Y, Zhao T, Ma B, Liu Y, et al. Kindlin 2 forms a transcriptional complex
 795 with β-catenin and TCF4 to enhance Wnt signalling. EMBO Rep. 2012 Aug;13(8):750–8.
- Kawamura E, Hamilton GB, Miskiewicz El, MacPhee DJ. Fermitin family homolog-2
 (FERMT2) is highly expressed in human placental villi and modulates trophoblast invasion.
 BMC Developmental Biology. 2018 Nov 1;18(1):19.
- Yasuda-Yamahara M, Rogg M, Frimmel J, Trachte P, Helmstaedter M, Schroder P, et al.
 FERMT2 links cortical actin structures, plasma membrane tension and focal adhesion
 function to stabilize podocyte morphology. Matrix Biology. 2018 Aug 1;68–69:263–79.
- Akter KA, Mansour MA, Hyodo T, Senga T. FAM98A associates with DDX1-C14orf166FAM98B in a novel complex involved in colorectal cancer progression. Int J Biochem Cell
 Biol. 2017 Mar;84:1–13.
- 805 71. Gao B, Li X, Li S, Wang S, Wu J, Li J. Pan-cancer analysis identifies RNA helicase DDX1 as a
 806 prognostic marker. Phenomics. 2022 Feb 1;2(1):33–49.
- Rapier-Sharman N, Krapohl J, Beausoleil EJ, Gifford KTL, Hinatsu BR, Hoffmann CS, et al.
 Preprocessing of Public RNA-Sequencing Datasets to Facilitate Downstream Analyses of
 Human Diseases. Data. 2021 Jul;6(7):75.

810 811 812	73.	Orjuela S, Huang R, Hembach KM, Robinson MD, Soneson C. ARMOR: An Automated Reproducible MOdular Workflow for Preprocessing and Differential Analysis of RNA-seq Data. G3 (Bethesda). 2019 Jul 9;9(7):2089–96.
813 814	74.	Köster J, Rahmann S. Snakemakea scalable bioinformatics workflow engine. Bioinformatics. 2012 Oct 1;28(19):2520–2.
815 816	75.	Babraham Bioinformatics - Trim Galore! [Internet]. [cited 2021 Jun 7]. Available from: https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/
817 818 819	76.	Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence Data [Internet]. [cited 2021 Jun 7]. Available from: https://www.bioinformatics.babraham.ac.uk/projects/fastqc/
820 821	77.	Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017 Apr;14(4):417–9.
822 823 824	78.	Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010 Jan 1;26(1):139–40.
825 826	79.	Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011 Jun 15;27(12):1739–40.
827 828	80.	Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012 Sep 1;40(17):e133.
829 830	81.	Nowicka M, Robinson MD. DRIMSeq: a Dirichlet-multinomial framework for multivariate count outcomes in genomics. F1000Res. 2016;5:1356.
831 832	82.	Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999 Jan 1;27(1):29–34.
833 834	83.	Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2013 Aug;8(8):1551–66.
835	84.	Nishimura D. BioCarta. Biotech Software & Internet Report. 2001 Jun 1;2(3):117–20.
836 837	85.	Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The Reactome Pathway Knowledgebase. Nucleic Acids Research. 2018 Jan 4;46(D1):D649–55.
838 839 840	86.	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
841	87.	Wickham H. ggplot2. WIREs Computational Statistics. 2011;3(2):180–5.


842 843	88.	Simoes R de M, Emmert-Streib F. Bagging Statistical Network Inference from Large-Scale Gene Expression Data. PLOS ONE. 2012 Mar 30;7(3):e33624.					
844	89.	Tennekes M, de Jonge E. TOP-DOWN DATA ANALYSIS WITH TREEMAPS. 2011;6.					
845 846	90.	Liaw A, Wiener M. Classification and Regression by randomForest. R News. 2002;2(3):18–22.					
847 848	91.	Scott TM, Jensen S, Pickett BE. A signaling pathway-driven bioinformatics pipeline for predicting therapeutics against emerging infectious diseases. F1000Res. 2021;10:330.					
849 850 851	92.	naomi-rapier-sharman. summarize_Pathways2Targets2_output [Internet]. 2022 [cited 2022 Apr 15]. Available from: https://github.com/naomi-rapier- sharman/summarize_Pathways2Targets2_output					
852 853							
854	Su	pporting information captions					
855							
856	S0 F	ile. B-Cell Non-Hodgkin's Lymphomas Transcriptomic Meta-Analysis: Supplementary					
857	Mate	rials Description. This document contains a guide to allow readers to easily navigate the					
858	supp	lementary files.					
859	S1 F	ile. PRISMA 2020 checklist for transparent meta-analysis reporting. This document					
860	conta	ains the PRISMA guidelines for reporting meta-analyses/systematic reviews and the					
861	manı	uscript location of required information.					
862	S2 Fi	le. Differentially expressed gene results (edgeR output). The entire BCNHL differentially					
863	expre	essed gene list produced by edgeR. The file is written in TSV format and can be successfully					
864	open	ed in Excel. Some genes in the original TSV file have more associated data than can fit on					
865	one l	ine. The genes in the file are ranked according to FDR, with the smallest FDRs at the top.					
866	Please note, the file also contains differential expression results for genes which were not						
867	signif	ficantly differentially expressed at the bottom. For description of column contents, please					
868	see S	0 File.					

869 S3 File. Differentially expressed splice variants (by gene; DRIMSeq output). The BCNHL

- differentially expressed splice variant results (by gene) produced by DRIMSeq. Genes are ranked
- according to adjusted p-value, with the lowest adjusted p-value at the top. NOTE: Should you
- desire to discover which transcripts of a certain gene are present in the BCNHL dataset, see the
- 873 "tx_ids" column in Supplementary File S1. For description of column contents, please see S0 File.
- 874 **S4 File. Differentially expressed gene ontology results (Camera output).** The BCNHL
- differentially expressed gene ontology results produced by Camera. No gene ontologies were
- significant after performing the FDR correction. For description of column contents, please see
- 877 S0 File.
- 878 **S5 File. Differentially regulated pathway results (SPIA output).** The BCNHL differentially
- 879 expressed pathway results produced by SPIA. For description of column contents, please see S0
- 880 File.
- 881 S6 File. Drug prediction results by gene (Pathways2Targets unsorted output). The raw drug
- 882 prediction results from Pathways2Targets2.R.
- 883 S7 File. Drug prediction results sorted by most significant pathways impacted
- 884 (Pathways2Targets sorted output). The sorted drug prediction results, ranked according to
- 885 which drugs impact the highest number of significantly modulated pathways.
- 886 **S8 File. Biomarker prediction results (randomForest output).** The ranked random forest
- biomarker prediction results. Sheet one contains all genes, and sheet two contains the random
- 888 forest results when the selection was narrowed to the top three genes.



*Excluded by automation. All other excluded records were excluded by a human.



BCNHL vs. Healthy

Signal transduction		Immune system	Endocrin system	e	Energy metabolism				Infectious diseases: bacterial	
(which was not certified by peer rev	1101/2022.04.28.22274444; this version view) is the author/funder, who has gra t is made available under a CC-BY 4.0 Signaling	posted April 29, 2022. The copyright hold red medRxiv a license to display the preprint International license . Membrane transport	for this preprint in perpetuity. Metab. of cofact. and vitam.		ansport and abolism types		cific	Cardiov.		A CONTRACTOR OF
Cancers: overview		growth	Folding, sorting and degradation	s	lervous system		1000	ment Metab. c	t of	disease Metab. of
Carb.	Infectious	Neuro– degen. diseases	Glycan biosynth. and metab.	x	and repair enobiot.	system Environ. adapt.		acids	Infec disea	bolvket. etious ases: asitic
metabolism	diseases: viral	Lipid metab.	Endocr. and metab. diseases	an Ni	nd metab. ucleotide etabolism	Bios of o sec	ynth. other	system	sys Tra	ns-Aging

0.0 0.2 0.4 0.6 0.8 1.0 1.2 Average Log2 Fold Change

1	
L	7
Г	٦.

 FERMT2 EDNRB YES1 FAM98B FKBP10 LAMA4 GJA1 RBFOX2 DCAF12 CSRP2 CDK1 SOCS6 PEX5 ANLN UBR5 PSTPIP2 PBK ZNF664 CENPF FBXO45 KIF14 TIMM8A NAPEPLD ZCCHC8 PSME4 LPAR1 BET1 DMXL2 COL1A2 VKORC1L1	
	MeanDecreaseAccuracy

